Archives

  • 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04
  • 2024-05
  • Almost all men are eligible to have

    2019-05-24

    Almost all men are eligible to have a vasectomy. It is highly effective, convenient, and easy to provide, and is also, along with female sterilisation, one of only two permanent methods of contraception. For these reasons, and to share contraceptive responsibilities, GS-7340 fumarate is widely chosen in regions and countries with high socioeconomic GS-7340 fumarate development and gender equality. Vasectomy prevalence is 12% in Northern America and 11% in Oceania and Northern Europe. In Canada it is the most widely used method: 22% of women rely on vasectomy, accounting for 31% of all modern method use. The UK, New Zealand, and South Korea have similar profiles, with vasectomy prevalence ranging from 17% to 21%, comprising 24% to 27% of modern method use. Australia, Belgium, Denmark, Spain, Switzerland, and the USA also have substantial vasectomy use, with prevalence ranging from 8% to 11%. In the USA, 175 000 to 350 000 vasectomies are done every year. The situation differs markedly in the world\'s 69 least developed countries: only 0·7% of women are able to rely on a partner\'s vasectomy. Vasectomy prevalence in Africa is 0·0%, with fewer than 100 000 men having accessed it. Of 54 African countries, only ten report measurable vasectomy use and only Swaziland (0·3%), Botswana (0·4%), and South Africa (0·7%) exceed 0·1% prevalence. Vasectomy is the least known modern method in most low-resource countries. Furthermore, the knowledge (or, more accurately, awareness) that does exist, among women and men alike, is often burdened by erroneous understandings that equate vasectomy with castration, impotence, and weakness (inability to work). When a man does desire vasectomy, skilled providers are generally unavailable to provide services. Although vasectomy is simpler to perform, less invasive, safer, and more cost effective than female sterilisation, less than one in 11 users of permanent methods in developing regions relies on vasectomy. However, all is not bleak. As greater education and participation of women, rapid urbanisation, and the spread of global communication continue to drive smaller desired family size in almost all countries, demand to limit future childbearing among married women continues to rise and now exceeds demand to space births in all regions except western Africa and middle Africa. The average age at which this occurs can be surprisingly low—eg, 29 years in Malawi, 28 years in Namibia, 24 years in Lesotho, and 23 years in Swaziland. Female sterilisation is the most widely used method worldwide, with 223 million women relying on it; another 28 million women rely on their partner\'s vasectomy. Malawi, one of the world\'s ten poorest countries, has achieved 9·7% female sterilisation prevalence; more than 170 000 procedures were provided there from 2008 to 2011 via public–private partnerships, free mobile services, and family planning-dedicated, non-physician providers. Thoughtful, male-centred programming has resulted in greater vasectomy use in Nepal (7·8% prevalence), Brazil (5·1%), and Colombia (3·4%). In Rwanda, pilot programmes have provided more than 1000 vasectomies annually.
    Globally, pneumonia remains the leading infectious cause of death in children younger than 5 years. Undernutrition, defined by wasting, stunting, and specific nutritional deficiencies, is associated with approximately half of all deaths in such children. Beyond having a direct impact on mortality, undernutrition increases the frequency and severity of pneumonia episodes, potentially representing a secondary immune deficiency that has not been well characterised. Undernutrition in a child with severe pneumonia requiring hospitalisation can also be associated with a diminished metabolic capacity to overcome the amplified physical and physiological demands of the illness, such as increased temperature, cardiac output, and work of breathing. Consequently, the presence of severe acute malnutrition can increase mortality from pneumonia 15-fold, and in a score of mortality risk among infants with pneumonia, very low weight-for-age and refusal to feed contributed as much to mortality risk as hypoxia.